Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Nanospectra

Nanospectra?uq=PEM9b6PF
2002 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$2.03M LATEST DEAL AMOUNT
11 INVESTORS
Description

Developer of tissue ablation therapies designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation and traditional focal therapies. The company's therapies utilize optical tunability for a new class of nanoparticles, called nanoshells, that convert light into heat and thermally destroy solid tumors, enabling physicians to treat their patients in an enhanced way.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Primary Office
  • 8285 El Rio Street
  • Suite 150
  • Houston, TX 77054
  • United States

+1 (713) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Nanospectra’s full profile, request a free trial.

Nanospectra Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Later Stage VC (Series B) 09-Feb-2017 $2.03M 00.00 000.00 Completed Clinical Trials - General
15. Later Stage VC (Series AA) 15-Dec-2015 00000 00.00 00.000 Completed Clinical Trials - General
14. Later Stage VC (Series AA) 29-Aug-2014 00000 00.000 00.000 Completed Clinical Trials - General
13. Later Stage VC (Series AA) 17-Jun-2013 00000 00.000 00.000 Completed Clinical Trials - General
12. Later Stage VC (Series AA) 03-Jun-2013 00.000 00.000 00.000 Completed Clinical Trials - General
11. Later Stage VC 16-Nov-2010 00000 00.000 Completed Clinical Trials - General
10. Grant 03-Aug-2010 00.00 00.000 Completed Clinical Trials - General
9. Later Stage VC 05-Jan-2009 00.00 00.000 Completed Clinical Trials - General
8. Corporate 03-Nov-2008 $250K $990K Completed Clinical Trials - General
7. Grant 15-Sep-2008 $350K $740K Completed Clinical Trials - General
To view this company’s complete deal history including valuation and funding, request access »

Nanospectra Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series AA 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Nanospectra Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Science Applications International Corporation Minority 000 0000 000000 0
Mercury Fund Venture Capital Minority 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Nanospectra Executive Team (8)

Name Title Board
Seat
Contact
Info
David Jorden Chief Executive Officer, Executive Director and Board Member
Glenn Goodrich Ph.D Acting Chief Operating Officer & Vice President, Process Development and Chemistry
Jon Schwartz Ph.D Director, Clinical Research
Jennifer West Ph.D Co-Founder and Board Member
Naomi Halas Ph.D Co-Founder

3 Former Executives

You’re viewing 5 of 8 executives. Get the full list »

Nanospectra Board Members (8)

Name Representing Role Since Contact
Info
Bradley Nyberg Self Board Member 000 0000
Brian Pryor Self Board Member 000 0000
David Bristol Jr. Self Board Member 000 0000
David Jorden Nanospectra Chief Executive Officer, Executive Director and Board Member 000 0000
Jennifer West Ph.D Nanospectra Co-Founder and Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 8 board members. Get the full list »